



MEN

FIRST CANCER SITE
LUNGLUNG
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

POLMONE

POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months		
	No. of subjects alive at interval beginning ▶	Person-years ▶	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR		
SECOND CANCER SITE			O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR		
ALL SITES, BUT SKIN AND LUNG	3377	177729	116474	1.09	149167	1.12	149167	1.31	116474	0.86	48891	1.13	8861	1.39	2908	1.28	1.62	2.03
HEAD AND NECK	383	177729	116474	2.37	149167	2.39	149167	2.55	116474	1.81	48891	2.72	8861	2.84	2908	1.97	1.24	1.27
ORAL CAVITY	111	177729	116474	3.00	149167	2.93	149167	2.38	116474	2.89	48891	3.36	8861	2.89	2908	1.32	0.42	0.40
PHARYNX	93	177729	116474	2.76	149167	2.77	149167	2.86	116474	1.91	48891	3.47	8861	2.80	2908	2.53	0.33	0.34
LARYNX	179	177729	116474	1.97	149167	2.03	149167	2.51	116474	1.35	48891	2.18	8861	2.83	2908	2.04	0.50	0.53
OESOPHAGUS	75	177729	116474	1.85	149167	1.90	149167	2.35	116474	1.05	48891	1.94	8861	2.76	2908	3.40	0.19	0.21
STOMACH	239	177729	116474	1.05	149167	1.05	149167	1.04	116474	0.88	48891	0.93	8861	1.62	2908	1.41	0.06	0.06
COLON RECTUM	502	177729	116474	0.99	149167	1.00	149167	1.07	116474	0.76	48891	1.01	8861	1.30	2908	1.17	-0.04	-0.01
COLON	356	177729	116474	1.03	149167	1.03	149167	1.10	116474	0.85	48891	1.00	8861	1.27	2908	1.42	0.05	0.06
RECTUM	146	177729	116474	0.90	149167	0.92	149167	1.00	116474	0.58	48891	1.04	8861	1.37	2908	0.60	-0.09	-0.08
LIVER	115	177729	116474	0.75	149167	0.79	149167	1.12	116474	0.36	48891	0.69	8861	1.44	2908	1.39	-0.22	-0.18
GALLBLADDER	41	177729	116474	1.04	149167	0.99	149167	0.61	116474	0.74	48891	1.26	8861	1.12	2908	1.02	0.01	0.00
PANCREAS	109	177729	116474	1.09	149167	1.06	149167	0.81	116474	1.06	48891	1.01	8861	1.44	2908	0.94	0.05	0.03
LUNG	92	177729	116474	0.13	149167	0.21	149167	0.85	116474	0.06	48891	0.15	8861	0.22	2908	0.21	-3.35	-3.04
SKIN MELANOMA	39	177729	116474	0.79	149167	0.74	149167	0.35	116474	0.74	48891	0.71	8861	1.22	2908	0.52	-0.06	-0.07
MESOTHELIOMA	6	177729	116474	0.31	149167	0.41	149167	1.32	116474	0.31	48891	0.36	8861	0.00	2908	0.67	-0.08	-0.06
KAPOSI SARCOMA	11	177729	116474	1.45	149167	1.29	149167	0.00	116474	1.50	48891	0.62	8861	4.34	2908	0.00	0.02	0.01
SOFT TISSUE	17	177729	116474	1.37	149167	1.37	149167	1.32	116474	1.18	48891	1.14	8861	3.07	2908	0.00	0.03	0.03
BONE	1	177729	116474	0.30	149167	0.27	149167	0.00	116474	0.00	48891	0.00	8861	2.02	2908	0.00	-0.01	-0.01
BREAST	10	177729	116474	1.27	149167	1.36	149167	2.08	116474	1.12	48891	0.30	8861	2.40	2908	5.26	0.01	0.02
PROSTATE	603	177729	116474	0.83	149167	0.84	149167	0.87	116474	0.67	48891	0.87	8861	0.96	2908	1.02	-0.68	-0.66
TESTIS	1	177729	116474	0.29	149167	0.26	149167	0.00	116474	0.80	48891	0.00	8861	0.00	2908	0.00	-0.01	-0.01
KIDNEY AND RENAL PELVIS	173	177729	116474	1.48	149167	1.63	149167	2.88	116474	1.55	48891	1.55	8861	1.33	2908	1.06	0.32	0.41
BLADDER AND URINARY TRACT	645	177729	116474	1.53	149167	1.54	149167	1.61	116474	1.02	48891	1.76	8861	1.85	2908	1.91	1.26	1.28
URINARY BLADDER	629	177729	116474	1.56	149167	1.57	149167	1.64	116474	1.03	48891	1.79	8861	1.90	2908	1.97	1.27	1.29
URINARY TRACT	16	177729	116474	0.89	149167	0.89	149167	0.90	116474	0.82	48891	1.05	8861	0.70	2908	0.75	-0.01	-0.01
BRAIN AND CENTRAL NERVOUS SYSTEM	29	177729	116474	0.68	149167	0.66	149167	0.57	116474	0.67	48891	0.81	8861	0.45	2908	0.35	-0.08	-0.08
THYROID	23	177729	116474	1.46	149167	1.77	149167	4.41	116474	1.89	48891	1.33	8861	0.79	2908	1.80	0.04	0.07
HODGKIN LYMPHOMA	4	177729	116474	0.55	149167	0.74	149167	2.18	116474	1.16	48891	0.32	8861	0.00	2908	0.00	-0.02	-0.01
NON-HODGKIN LYMPHOMA	89	177729	116474	0.85	149167	0.88	149167	1.11	116474	0.56	48891	0.85	8861	1.14	2908	1.59	-0.09	-0.07
MYELOMA	30	177729	116474	0.62	149167	0.73	149167	1.66	116474	0.30	48891	0.48	8861	1.69	2908	0.56	-0.10	-0.07
LEUKAEMIAS	87	177729	116474	1.04	149167	1.10	149167	1.60	116474	0.79	48891	1.01	8861	1.69	2908	1.01	0.02	0.05
LYMPHOID LEUKAEMIAS	32	177729	116474	0.79	149167	0.96	149167	2.33	116474	0.49	48891	0.75	8861	1.44	2908	1.08	-0.05	-0.01
MYELOID LEUKAEMIAS	46	177729	116474	1.23	149167	1.16	149167	0.64	116474	1.01	48891	1.07	8861	2.19	2908	1.08	0.05	0.03
OTHER LEUKAEMIAS	9	177729	116474	1.57	149167	1.68	149167	2.50	116474	1.43	48891	2.48	8861	0.00	2908	0.00	0.02	0.02
OTHER AND ILL DEFINED SITES	145	177729	116474	0.76	149167	0.86	149167	1.68	116474	0.78	48891	0.62	8861	0.87	2908	1.21	-0.25	-0.15

Decrease/Difetto
Increase/Eccesso

Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE
LUNGLUNG
POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

POLMONE
POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	Person-years ▶	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
SECOND CANCER SITE			O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND LUNG	587	49229	1.13	1.17	1.46	0.94	1.22	1.25	1.23	1.39	1.77					
HEAD AND NECK	20	20	2.81	2.51	0.00	2.55	2.53	5.22	0.00	0.26	0.22					
ORAL CAVITY	6	6	1.59	1.42	0.00	1.62	1.20	3.22	0.00	0.05	0.03					
PHARYNX	6	6	3.81	3.41	0.00	3.79	1.42	12.15	0.00	0.09	0.08					
LARYNX	8	8	4.52	4.05	0.00	3.39	5	6.36	1	3.56	0.00	0.00	0.13	0.11		
OESOPHAGUS	6	6	2.27	2.69	2	6.10	2	2.29	3	2.58	1	2.34	0.00	0.07	0.09	
STOMACH	22	22	0.70	0.71	3	0.74	6	0.57	10	0.73	4	0.81	2	0.96	-0.19	-0.19
COLON RECTUM	106	106	1.25	1.23	11	1.07	27	0.97	47	1.26	22	1.58	10	1.69	0.43	0.40
COLON	78	78	1.28	1.26	8	1.09	22	1.10	36	1.35	12	1.19	8	1.86	0.35	0.32
RECTUM	28	28	1.17	1.16	3	1.04	5	0.63	11	1.05	10	2.58	2	1.23	0.08	0.08
LIVER	14	14	0.94	0.90	1	0.55	1	0.20	5	0.77	6	2.48	2	1.94	-0.02	-0.03
GALLBLADDER	9	9	0.78	0.85	2	1.38	1	0.26	5	1.00	1	0.54	2	2.59	-0.05	-0.03
PANCREAS	35	35	1.60	1.59	4	1.50	7	0.99	21	2.21	6	1.65	1	0.63	0.27	0.26
LUNG	11	11	0.31	0.60	13	3.12	0	0.00	3	0.19	5	0.84	3	1.17	-0.50	-0.29
SKIN MELANOMA	12	12	1.19	1.16	1	0.88	1	0.31	8	1.79	2	1.20	1	1.46	0.04	0.03
MESOTHELIOMA	0	0	0.00	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
KAPOSI SARCOMA	0	0	0.00	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
SOFT TISSUE	4	4	1.75	1.96	1	3.74	2	2.67	1	0.99	1	2.70	0	0.00	0.03	0.04
BONE	2	2	3.26	4.36	1	13.54	0	0.00	0	0.00	2	20.38	0	0.00	0.03	0.04
BREAST	141	141	0.99	1.01	18	1.11	41	0.88	72	1.14	20	0.88	8	0.88	-0.02	0.02
CERVIX UTERI	10	10	1.40	1.37	1	1.14	5	2.01	2	0.63	2	1.86	1	2.48	0.06	0.05
CORPUS UTERI	19	19	0.73	0.72	2	0.67	4	0.46	10	0.86	5	1.20	0	0.00	-0.15	-0.15
OVARY	16	16	0.92	0.98	3	1.46	5	0.86	5	0.65	4	1.45	2	1.79	-0.03	-0.01
KIDNEY AND RENAL PELVIS	22	22	1.61	1.45	0	0.00	10	2.27	9	1.50	3	1.32	0	0.00	0.17	0.12
BLADDER AND URINARY TRACT	42	42	2.02	1.88	2	0.79	12	1.76	23	2.52	2	0.58	5	3.41	0.43	0.38
URINARY BLADDER	40	40	2.06	1.93	2	0.86	10	1.58	23	2.71	2	0.63	5	3.67	0.42	0.37
URINARY TRACT	2	2	1.38	1.23	0	0.00	2	4.21	0	0.00	0	0.00	0	0.00	0.01	0.01
BRAIN AND CENTRAL NERVOUS SYSTEM	8	8	0.98	0.99	1	1.06	1	0.37	2	0.56	3	2.25	2	3.62	0.00	0.00
THYROID	16	16	1.60	2.17	8	7.59	6	1.86	6	1.34	3	1.84	1	1.56	0.12	0.24
HODGKIN LYMPHOMA	0	0	0.00	2.08	3	19.56	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	0.03
NON-HODGKIN LYMPHOMA	21	21	1.01	1.16	6	2.45	7	1.02	11	1.20	2	0.59	1	0.70	0.00	0.07
MYELOMA	12	12	1.25	1.20	1	0.86	3	0.95	8	1.89	1	0.64	0	0.00	0.05	0.04
LEUKAEMIAS	18	18	1.35	1.47	4	2.43	1	0.23	10	1.71	5	2.32	2	2.21	0.09	0.13
LYMPHOID LEUKAEMIAS	6	6	1.02	1.36	3	4.06	0	0.00	3	1.16	3	3.22	0	0.00	0.00	0.04
MYELOID LEUKAEMIAS	11	11	1.73	1.69	1	1.30	1	0.48	6	2.16	2	1.92	2	4.48	0.09	0.09
OTHER LEUKAEMIAS	1	1	0.92	0.82	0	0.00	0	0.00	1	2.13	0	0.00	0	0.00	0.00	0.00
OTHER AND ILL DEFINED SITES	32	32	0.82	1.08	15	3.09	12	0.94	13	0.77	4	0.63	3	1.09	-0.14	0.06

Decrease/Difetto
Increase/Eccesso

Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio